# 1. Financial Performance ## A. Key Figures * **Consolidated Revenue:** **INR30.8 Cr** (Q1 FY'26) (+74.2% YoY) · **INR17.4 Cr** (Q1 FY'25) * EBITDA: INR48.5 Cr (Q1 FY'26) (+85.6% QoQ, -11.6% YoY) · INR26.2 Cr (Q4 FY'25) · INR54.9 Cr (Q1 FY'25) * EBITDA Margin: 16% (Q1 FY'26) (+630 bps QoQ, -300 bps YoY) · 9.7% (Q4 FY'25) · 19% (Q1 FY'25) * PAT: INR7.7 Cr (Q1 FY'26) (+163% QoQ, -47% YoY) · -INR12.2 Cr (Q4 FY'25) · INR14.7 Cr (Q1 FY'25) * PAT Margin: 2.5% (Q1 FY'26) · -4.5% (Q4 FY'25) · 5.1% (Q1 FY'25) * Consolidated EBITDA: -INR0.74 Cr (Q1 FY'26) · -INR2.7 Cr (Q1 FY'25) * **Debt & Capitalization:** **INR302 Cr** consolidated debt · **3x** gearing ratio * **Standalone Net Cash:** **INR10 Cr** ## B. Revenue Growth * **Modest Top-Line Expansion:** Consolidated revenue growth of 2% YoY reflects **strong domestic sales volumes** and improved channel engagement, partially offset by a sharp decline in FOSO segment revenue. * **Segment Divergence:** FOSO revenue collapsed from prior-year levels, while FOSM remained marginal, indicating a strategic or operational shift in overseas operations. ## C. Profitability Trends * **Profit Recovery Amid Margin Pressure:** PAT rebounded strongly QoQ from negative to positive territory, though YoY profitability declined significantly despite gross margin gains from supply chain optimization and value-engineered implants. * **EBITDA Volatility:** Marked YoY EBITDA decline across entities, but standalone EBITDA improved QoQ; consolidated EBITDA loss narrowed sharply by **72% YoY**, signaling operational turnaround. * **Margin Rebound from Low Base:** EBITDA margin more than doubled QoQ from a depressed level, though still below prior-year peak, weighed down by structural and mix-related headwinds. * **Cost Rationalization Focus:** Management targeting **30% reduction in COGS** via manufacturing efficiencies and warehouse optimization to drive sustainable margin expansion. ## D. Balance Sheet & Capital Structure * **Resilient Standalone Position:** Company maintains a strong standalone net cash balance and low leverage, providing financial flexibility despite consolidated debt of INR302 Cr. * **Capital Efficiency Push:** Annualized ROCE of **5%** in the quarter, with initiatives underway to improve asset utilization and reduce inventory overhang. ## E. Cash Flow & Working Capital * **Working Capital Optimization:** Order-to-cash improvements and inventory reduction efforts underway to enhance cash conversion and support ROCE expansion. --- # 2. Hospital & Segment Performance ## A. Key Figures * **Mature Hospital EBITDA:** **₹32 Cr** (Q1 FY26) (~36% margin) · **55%** of total EBITDA * **5–10 Year Hospitals EBITDA Margin:** **~17%** * **0–5 Year Hospitals ARPOB:** **~₹89,000** (driven by 56% international patients) * **Standalone Hospital Revenue:** **₹242 Cr** (Q1 FY26) (+1% QoQ, ~flat YoY) ## B. Mature Hospitals * **Sustained Profitability:** Mature hospitals (10+ years) remain highly profitable with near **36% EBITDA margins**, despite declining contribution to total EBITDA, reflecting successful portfolio diversification. * **Clinical Leadership:** **25 transplants** completed in the quarter highlight clinical strength in complex procedures, reinforcing brand credibility. * **Domestic Focus:** Mature facilities increasingly serve domestic patients, resulting in lower ARPOB; profitability remains strong despite lower revenue per bed. ## C. Newer Hospitals * **Growth Trajectory:** Hospitals aged 5–10 years show **strong double-digit growth momentum** and solid margins (~17%), poised to outpace mature units due to available capacity and expansion. * **Sanar Turnaround Underway:** Sanar International Hospital on path to profitability, targeting **single-digit EBITDA margins** in current fiscal and **20–25%** over 4–5 years, supported by NABH accreditation and insurance tie-ups. * **High ARPOB from International Mix:** Newer hospitals derive **56% of revenue from international patients**, driving a significantly higher ARPOB (~₹89,000), though profitability is evaluated separately. ## D. Standalone vs Consolidated * **MedTech Breaks Even:** Shalby MedTech achieved **positive standalone EBITDA** (₹2 Cr) after prior losses, driven by **domestic volume surge**, **channel optimization**, and **robotics partnerships**. * **Hospital Revenue Stabilized:** Standalone hospital revenue flat YoY but up slightly QoQ, indicating stabilization post-restructuring; growth now led by MedTech and newer facilities. --- # 3. Volume & Utilization Metrics ## A. Key Figures * Occupied Beds: 639 (–4.5%) * **Overall Occupancy Rate:** **45%** * **ARPOB:** **₹45,673** (+3%) · **Shalby Sanar ARPOB:** **₹90,000** * ALOS: 3.38 days ## B. Occupancy Trends * **Occupancy Under Pressure:** System-wide bed occupancy declined to **45%**, below the 50% threshold, driven by lower international patient inflows and subdued demand, particularly at Shalby Sanar where occupancy fell to **22%**. * **Strategic Focus Shift:** Management emphasizes **outpatient and inpatient account growth** over occupancy, acknowledging its limitations as a standalone metric amid fluctuating ALOS and patient mix. * **Growth Initiatives Underway:** Efforts to boost utilization include targeted patient segment outreach (e.g., dermatology), attracting more consultants, and refining **economy-class packages**, with potential pricing adjustments under review. ## C. Revenue & Utilization Dynamics * **ARPOB Expansion Driven by Efficiency:** Strong **double-digit growth in ARPOB** reflects higher throughput from short-stay surgeries and technological advancements enabling faster recoveries (e.g., CABG stays halved). * **ALOS Decline Reflects Procedural Mix:** Shorter stays are primarily due to increased daycare and minimally invasive procedures in centers like **Naroda and Surat**, not necessarily improved efficiency; ALOS is not viewed as a core performance indicator when occupancy is low. * **Geographic and Specialty Premiums:** ARPOB varies significantly by **location (metro vs. Tier 1/2)** and **specialty mix**, with high-value procedures like **arthroplasty** contributing disproportionately to revenue per occupied bed. --- # 4. Payer & Revenue Mix ## A. Key Figures * **Payer Mix:** **36%** self-pay · **40%** insurance · **24%** government * **Revenue Split:** **75%** government/self-pay · **25%** TPA * **International Revenue:** **₹15 Cr** (₹2 Cr Shalby, ₹13 Cr Sanar) * **International Patient Share:** Fell from **65–70%** to **56%** of total ## B. Self-Pay & Insurance * **Pricing Discipline:** Self-paying patients charged **10%+ more** than insurance (Mediclaim) patients, with standard of care rates shared across payers, limiting discounting flexibility. * **Strategic Rate Alignment:** Hospital required to reduce charges by **5–10%** for TPA/insurance patients under MOU, despite uniform SOC, creating structural pricing asymmetry. * **Revenue Stability:** Insurance tie-ups renewed every 2–3 years, covering both GIPSA networks and corporate PPAs, supporting predictable cash flows. ## C. Government Schemes * **Volume Target Shift:** Management aims to increase government patient volume to **30% of occupancy**, despite current 24% revenue contribution, signaling strategic expansion in public schemes. ## D. International Patients * **Domestic Pivot:** Strategic rebalancing at Sanar Hospital to grow domestic patient base, reducing reliance on international patients (down from 65% to 56%). * **Growth in Sourcing:** International patient inflow supported by **ministry-level agreements** and partnerships with **global medical tourism platforms**, with expansion expected. * **Branding Opportunity:** Investor inquiry highlights potential for **differentiated clinical branding**, **bundled care**, and **outcome-linked pricing** to enhance international competitiveness. --- # 5. Implant Business & Sales ## A. Key Figures * **Total Implant Components Sold:** **14,076** units (+65.4% YoY) · **Standalone Sales:** **9,317** units (+228.4% YoY) ## B. Unit Sales Volume * **Steady Volume Growth:** Implant unit sales show consistent year-on-year expansion, reflecting improving market adoption and commercial execution. * **Pipeline & Product Strategy:** New innovation projects underway to strengthen the product pipeline, with focus on scaling established brands like **TUKS** to capture greater market share. * **Supply Chain Optimization:** Multi-vendor sourcing strategy targeting **15–20% cost reduction** to offset tariffs and improve freight efficiency. * **Profit Contribution Outlook:** Implant business expected to eventually contribute **25% of EBITDA**, driven by global expansion and large addressable market, though not in the near term. * **Orthopedic Growth Runway:** With the global orthopedic market valued at **$30 billion**, current operations represent early-stage penetration, supporting long-term investment and scale potential. ## C. Robotic Partnerships * **Technology Integration:** Two new products set for global launch this year, supported by advancing robotics collaboration with **CUREXO** to enhance surgical precision and system integration. * **Revenue Model Diversification:** Standalone income generated via **robotic rentals** and **consumables monetization** through strategic partnerships. ## D. Global Expansion * **Targeted Geographic Growth:** Sales push focused on --- # 6. Risks & Geopolitical Factors ## A. Key Figures * Shalby Sanar Revenue: **₹23.25 Cr** (Q1) (–2.2%) · **₹23.7 Cr** (Q1 prior) * **Government Receivables:** **180 days** average (RGHS/Ayushman) * **Middle East Patient Share:** **45–50%** of total inflow at Sanar ## B. Middle East Disruptions * **Geopolitical Headwinds:** Revenue and occupancy at Shalby Sanar pressured by war-related disruptions in Middle East patient inflows, with impact lasting ~30 days in Q1. * **Recovery Underway:** Occupancy is rebounding in the current quarter as regional conditions stabilize and patient flows normalize. ## C. Doctor Transition & Network Performance * **Operational Turbulence:** Broader network occupancy decline attributed to **doctor transitions**, **payer mix shift** away from government cases, and localized staffing volatility at Sanar. * **Strategic Selectivity:** Franchise expansion moderated by stringent partner vetting to safeguard brand quality, following past underperformance by select franchisees. ## D. Insurance & Receivables Pressure * **Persistent Delays:** Government scheme collections remain slow, averaging **180 days**, with no meaningful improvement over the past 2–3 years. * **Industry Pushback:** Company joins hospital collective in withholding support from non-responsive insurers citing **untimely payments** and **5-year stale rate agreements**. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Target:** **$100 Mn** implant business goal (4–5 years) * **Top Line Growth (FY '26):** **12%–15%** double-digit growth expected * **Occupancy Rate (FY '26):** **85%–90%** average annual target ## B. Revenue Projections * **Revised Implant Timeline:** $100 million implant revenue target now expected in 4–5 years due to supply chain delays and new product development cycles. * **Balanced Growth Trajectory:** Domestic business poised to grow at pace with international operations, fueled by rising patient inflows from UP, Bihar, Madhya Pradesh, and Rajasthan. * **Robust FY'26 Outlook:** Double-digit top-line expansion anticipated, supported by doctor investments and strong business momentum, with **corresponding EBITDA margin improvements**. ## C. Occupancy Targets * **High Utilization Guidance:** Facilities on track for near-full utilization, with average annual occupancy targeted at 85%–90% in FY '26. ## D. Margin Expectations * **Margin Enhancement Levers:** Strategic focus on product innovation, customer segmentation, COGS reduction, and supply chain optimization to drive profitability.